Converted acute toxicity point estimate according to Table 3.1.2 of Annex I. , ‘006-046-00-8, bendiocarb (ISO); 2,2-dimethyl-1,3-benzodioxol-4-yl N-methylcarbamate; 2,2-dimethyl-1,3-benzodioxol-4-yl methylcarbamate ,245-216-8,22781-23-3, Acute Tox. 3 Acute Tox. 3 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 , H331 H311 H300 H400 H410 , GHS06 GHS09 Dgr , H331 H311 H300 H410 ,, M = 10 M = 100’ ,, ‘604-057-00-8,reaction mass of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n = 5 or 6,401-680-5,—,Aquatic Chronic 4,H413,,H413’,,,, ‘605-023-00-5, 5-chloro-2-(4-chlorophenoxy)phenol; [DCPP] ,429-290-0,3380-30-1, Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H318 H400 H410 , GHS05 GHS09 Dgr , H318 H410 ,, M = 10 M = 10’ ,, ‘606-041-00-6,2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one,400-600-6,71868-10-5, Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 , H360FD H302 H411 , GHS08 GHS07 GHS09 Dgr , H360FD H302 H411’ ,,,, ‘607-123-00-4, 2,3-epoxypropyl methacrylate; glycidyl methacrylate ,203-441-9,106-91-2, Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 1 Eye Dam. 1 Skin Corr. 1C Skin Sens. 1 , H350 H341 H360F H311 H302 H335 H372 (respiratory tract) (inhalation) H318 H314 H317 , GHS08 GHS06 GHS05 Dgr , H350 H341 H360F H311 H302 H335 H372 (respiratory tract) (inhalation) H314 H317 ,,,D’, ‘608-055-00-8, fipronil (ISO); (±)-5-amino-1-(2,6-dichloro-α,α,α-trifluoro-para-tolyl)-4-trifluoromethylsulfinyl-pyrazole-3-carbonitrile ,424-610-5,120068-37-3, Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H301 H311 H331 H372* H400 H410 , GHS06 GHS08 GHS09 Dgr , H301 H311 H331 H372* H410 ,, M = 1 000 M = 10 000’ ,, ‘612-150-00-X, spiroxamine (ISO); 8-tert-butyl-1,4-dioxaspiro[4.5]decan-2-ylmethyl(ethyl)(propyl)amine ,—,118134-30-8, Repr. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H361d H332 H312 H302 H373 (eye) H315 H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H361d H332 H312 H302 H373 (eye) H315 H317 H410 ,, M = 100 M = 100’ ,, ‘613-318-00-5, fenpyrazamine (ISO); S-allyl 5-amino-2,3-dihydro-2-isopropyl-3-oxo-4-(o-tolyl)pyrazole-1-carbothioate; S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydropyrazole-1-carbothioate ,—,473798-59-3,Aquatic Acute 1 Aquatic Chronic 1, H400 H410 , GHS09 Wng ,H410,, M = 10 M = 1’ ,, ‘614-001-00-4, nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine ,200-193-3,54-11-5, Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 , H330 H310 H300 H411 , GHS06 GHS09 Dgr , H330 H310 H300 H411 ,, inhalation: ATE = 0.19 mg/L (dusts or mists) dermal: ATE = 70 mg/kg oral: ATE = 5 mg/kg’ ,, ‘615-013-00-2, cyanamide; carbamonitril ,206-992-3,420-04-2, Carc. 2 Repr. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 2 Skin Corr. 1 Skin Sens. 1 Eye Dam. 1 Aquatic Chronic 3 , H351 H361fd H311 H301 H373 (thyroid) H314 H317 H318 H412 , GHS08 GHS06 GHS05 Dgr , H351 H361fd H311 H301 H373 (thyroid) H314 H317 H412’ ,,,, ‘616-006-00-7, dichlofluanid (ISO); N-[(dichlorofluoromethyl)thio]-N′,N′-dimethyl-N-phenylsulfamide ,214-118-7,1085-98-9, Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 , H332 H319 H317 H400 , GHS07 GHS09 Wng , H332 H319 H317 H400 ,,M = 10’,, ‘616-094-00-7,3,3′-dicyclohexyl-1,1′-methylenebis(4,1-phenylene)diurea,406-370-3,58890-25-8,Aquatic Chronic 4,H413,,H413’,,,, ‘650-032-00-X,cyproconazole (ISO); (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol,—,94361-06-5, Repr. 1B Acute Tox. 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 , H360D H301 H373 (liver) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H301 H373 (liver) H410 ,, M = 10 M = 1’ ,, ‘047-003-00-3, silver zinc zeolite (Zeolite, LTA framework type, surface-modified with silver and zinc ions) [This entry covers LTA (Linde Type A) framework type zeolite which has been surface-modified with both silver and zinc ions at contents Ag+ 0,5 %-6 %, Zn2 + 5 %-16 %, and potentially with phosphorus, NH4+, Mg2+ and/or Ca2+ each at level < 3 %] ,—,130328-20-0, Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H361d H315 H318 H400 H410 , GHS08 GHS05 GHS09 Dgr , H361d H315 H318 H410 ,, M = 100 M = 100’ ,, ‘048-012-00-5,cadmium carbonate,208-168-9,513-78-0, Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H350 H340 H332 H312 H302 H372 (kidney, bone) H400 H410 , GHS08 GHS07 GHS09 Dgr , H350 H340 H332 H312 H302 H372 (kidney, bone) H410 ,,,A1’, ‘048-013-00-0,cadmium hydroxide; cadmium dihydroxide,244-168-5,21041-95-2, Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H350 H340 H332 H312 H302 H372 (kidney, bone) H400 H410 , GHS08 GHS07 GHS09 Dgr , H350 H340 H332 H312 H302 H372 (kidney, bone) H410 ,,,A1’, ‘048-014-00-6, cadmium nitrate; cadmium dinitrate ,233-710-6,10325-94-7, Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H350 H340 H332 H312 H302 H372 (kidney, bone) H400 H410 , GHS08 GHS07 GHS09 Dgr , H350 H340 H332 H312 H302 H372 (kidney, bone) H410 ,, Carc. 1B; H350: C ≥ 0,01 % ,A1’, ‘050-030-00-3,dibutyltin dilaurate; dibutyl[bis(dodecanoyloxy)]stannane,201-039-8,77-58-7, Muta. 2 Repr. 1B STOT RE 1 , H341 H360FD H372 (immune system) , GHS08 Dgr , H341 H360FD H372 (immune system)’ ,,,, ‘603-235-00-2, linalool; 3,7-dimethyl-1,6-octadien-3-ol; dl-linalool; [1] coriandrol; (S)-3,7-dimethyl-1,6-octadien-3-ol; d-linalool; [2] licareol; (R)-3,7-dimethyl-1,6-octadien-3-ol; l-linalool [3] , 201-134-4 [1] 204-810-7 [2] 204-811-2 [3] , 78-70-6 [1] 126-90-9 [2] 126-91-0 [3] ,Skin Sens. 1B,H317, GHS07 Wng ,H317’,,,, ‘604-093-00-4, clorofene; chlorophene; 2-benzyl-4-chlorophenol ,204-385-8,120-32-1, Carc. 2 Repr. 2 Acute Tox. 4 Skin Irrit. 2 Skin Sens. 1 Eye Dam. 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 , H351 H361f H332 H315 H317 H318 H373 (kidney) H400 H410 , GHS08 GHS05 GHS07 GHS09 Dgr , H351 H361f H332 H315 H317 H318 H373 (kidney) H410 ,, M = 1 M = 100’ ,, ‘606-150-00-9,clethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-chloroallyloxyimino]propyl}-5-[(2RS)-2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-one,—,99129-21-2, Acute Tox. 4 Skin Sens. 1 Aquatic Chronic 3 , H302 H317 H412 , GHS07 Wng , H302 H317 H412 ,EUH066’,,, ‘606-151-00-4,anthraquinone,201-549-0,84-65-1,Carc. 1B,H350, GHS08 Dgr ,H350’,,,, ‘607-720-00-X, nonadecafluorodecanoic acid; [1] ammonium nonadecafluorodecanoate; [2] sodium nonadecafluorodecanoate [3] , 206-400-3 [1] 221-470-5 [2] [3] , 335-76-2 [1] 3108-42-7 [2] 3830-45-3 [3] , Carc. 2 Repr. 1B Lact. , H351 H360Df H362 , GHS08 Dgr , H351 H360Df H362’ ,,,, ‘607-721-00-5, N,N′-methylenedimorpholine; N,N′-methylenebismorpholine; [formaldehyde released from N,N′-methylenebismorpholine]; [MBM] ,227-062-3,5625-90-1, Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Skin Sens. 1 Eye Dam. 1 , H350 H341 H332 H312 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 H318 , GHS08 GHS07 GHS05 Dgr , H350 H341 H332 H312 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 ,EUH071,, 8 9’ , ‘607-722-00-0, 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; epsilon-momfluorothrin ,—,1065124-65-3, Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 , H302 H371 (nervous system) H400 H410 , GHS07 GHS08 GHS09 Wng , H302 H371 (nervous system) H410 ,, M = 100 M = 100’ ,, ‘607-723-00-6, tefluthrin (ISO); 2,3,5,6-tetrafluoro-4-methylbenzyl (1RS,3RS)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropanecarboxylate ,—,79538-32-2, Acute Tox. 1 Acute Tox. 2 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 , H330 H310 H300 H400 H410 , GHS06 GHS09 Dgr , H330 H310 H300 H410 ,, M = 10 000 M = 10 000’ ,, ‘612-290-00-1, reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2); [formaldehyde released from 3,3′-methylenebis[5-methyloxazolidine]; formaldehyde released from oxazolidin]; [MBO] ,—,—, Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 3 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 , H350 H341 H332 H311 H302 H373 (gastrointestinal tract, respiratory tract) H314 H318 H317 H411 , GHS08 GHS06 GHS05 GHS09 Dgr , H350 H341 H332 H311 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 H411 ,EUH071,, 8 9’ , ‘612-291-00-7, reaction products of paraformaldehyde with 2-hydroxypropylamine (ratio 1:1); [formaldehyde released from α,α,α-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol]; [HPT] ,—,—, Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 , H350 H341 H332 H302 H373 (gastrointestinal tract, respiratory tract) H314 H318 H317 H411 , GHS08 GHS07 GHS05 GHS09 Dgr , H350 H341 H332 H302 H373 (gastrointestinal tract, respiratory tract) H314 H317 H411 ,EUH071,, 8 9’ , ‘612-292-00-2,methylhydrazine,200-471-4,60-34-4,Carc. 1B,H350, GHS08 Dgr ,H350’,,,, ‘613-321-00-1, (RS)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; medetomidine ,—,86347-14-0, Acute Tox. 2 Acute Tox. 2 STOT SE 3 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H330 H300 H336 H370 (eye) H372 H400 H410 , GHS06 GHS08 GHS09 Dgr , H330 H300 H336 H370 (eye) H372 H410 ,, M = 1 M = 100’ ,, ‘613-322-00-7, triadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; α-tert-butyl-β-(4-chlorophenoxy)-1H-1,2,4-triazole-1-ethanol ,259-537-6,55219-65-3, Repr. 1B Lact. Acute Tox. 4 Aquatic Chronic 2 , H360 H362 H302 H411 , GHS08 GHS07 GHS09 Dgr , H360 H362 H302 H411’ ,,,, ‘613-323-00-2, terbuthylazine (ISO); N-tert-butyl-6-chloro-N′-ethyl-1,3,5-triazine-2,4-diamine ,227-637-9,5915-41-3, Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 , H302 H373 H400 H410 , GHS07 GHS08 GHS09 Wng , H302 H373 H410 ,, M = 10 M = 10’ ,, ‘613-324-00-8, quinolin-8-ol; 8-hydroxyquinoline ,205-711-1,148-24-3, Repr. 1B Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H301 H318 H317 H400 H410 , GHS08 GHS06 GHS05 GHS09 Dgr , H360D H301 H318 H317 H410 ,, M = 1 M = 1’ ,, ‘613-325-00-3, thiacloprid (ISO); (Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazolidin-2-ylidenecyanamide; {(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide ,—,111988-49-9, Carc. 2 Repr. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 , H351 H360FD H332 H301 H336 H400 H410 , GHS08 GHS06 GHS09 Dgr , H351 H360FD H332 H301 H336 H410 ,, M = 100 M = 100’ ,, ‘616-221-00-6, hexaflumuron (ISO); 1-(3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl)-3-(2,6-difluorobenzoyl)urea ,401-400-1,86479-06-3, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 000 M = 10 000’ ,, ‘616-222-00-1, penthiopyrad (ISO); (RS)-N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxamide ,—,183675-82-3, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 M = 1’ ,, ‘616-223-00-7, carbetamide (ISO); (R)-1-(ethylcarbamoyl)ethyl carbanilate; (2R)-1-(ethylamino)-1-oxopropan-2-yl phenylcarbamate ,240-286-6,16118-49-3, Carc. 2 Repr. 1B Acute Tox. 4 Aquatic Chronic 2 , H351 H360D H302 H411 , GHS08 GHS07 GHS09 Dgr , H351 H360D H302 H411’ ,,,,